Shanghai Shyndec Pharmaceutical Co., Ltd. (SHA:600420)

China flag China · Delayed Price · Currency is CNY
10.61
-0.13 (-1.21%)
Mar 19, 2026, 1:14 PM CST
Market Cap14.40B -4.2%
Revenue (ttm)9.36B -14.4%
Net Income944.38M -12.9%
EPS0.70 -12.9%
Shares Out1.34B
PE Ratio15.25
Forward PEn/a
Dividend0.30 (2.79%)
Ex-Dividend Daten/a
Volume4,407,260
Average Volume10,929,629
Open10.67
Previous Close10.74
Day's Range10.60 - 10.72
52-Week Range9.69 - 11.80
Beta0.33
RSI44.98
Earnings DateMar 28, 2026

About SHA:600420

Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company offers 6-APA, potassium clavulanate series, diclofenac sodium extended release tablets, urine-derived biochemical products, nifedipine controlled release tablets, azithromycin, ceftriaxone sodium for injection, methylprednisolone sodium succinate for injection, cefuroxime tablets/capsules, ampicillin acid, penicillin industrial potassium salt, Touboke Yuekui granules/capsules, remifentanil hydr... [Read more]

Sector Healthcare
Founded 2000
Employees 11,472
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600420
Full Company Profile

Financial Performance

In 2025, SHA:600420's revenue was 9.36 billion, a decrease of -14.40% compared to the previous year's 10.94 billion. Earnings were 944.38 million, a decrease of -12.85%.

Financial Statements